Nogo receptor antagonists and methods of increasing neurite outgrowth
View Patent ↗Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
1. A method of treating a central nervous system (CNS) disease, disorder, or injury in a mammal selected from the group comprising stroke, spinal cord injury, optic neuritis, and glaucoma, comprising administering to a mammal in need of treatment an effective amount of an agent comprising a NogoR polypeptide variant comprising:
a sNogoR310 polypeptide, comprising the amino acid sequence of residues 27-310 of SEQ ID NO: 58; and
an antibody fragment, crystallizable (Fc):
wherein the Fc is joined to the sNogoR310 c-terminus,
wherein the NogoR variant inhibits neurite outgrowth inhibition.
2. The method of claim 1 wherein the subject receives a NogoR polypeptide variant in combination with another therapy.
3. The method of claim 1 , wherein the agent comprises a dimeric peptide comprising two of the NogoR variants.
4. A method of enhancing neurite outgrowth comprising administering to a mammal in need of treatment an effective amount of an agent comprising a NogoR polypeptide variant comprising:
a sNogoR310 polypeptide, comprising the amino acid sequence of residues 27-310 of SEQ ID NO: 58: and
an antibody fragment, crystallizable (Fc);
wherein the Fc is joined to the sNogoR310 c-terminus,
wherein the NogoR variant inhibits neurite outgrowth inhibition.
5. The method of claim 1 , wherein the CNS disease, disorder, or injury is a spinal cord injury.